Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic human neural stem cells (Casa Sollievo della Sofferenza)
- Development stage
- Unknown
- Lead developer
- Casa Sollievo della Sofferenza
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebroventricular
01
Overview
Allogeneic human neural stem cells (hNSCs), specifically the cell line 03/14b, is an investigational cell therapy developed by Casa Sollievo della Sofferenza IRCCS in collaboration with Revert Onlus. These cells are derived from fetal brain tissue obtained from a single miscarried donor and are produced under Good Manufacturing Practice (GMP) conditions. The therapy is administered via intracerebroventricular injection and is currently being evaluated in Phase I clinical trials for the treatment of secondary progressive multiple sclerosis (SPMS). The mechanism of action is thought to involve neuroprotection, immunomodulation, and potential remyelination within the central nervous system, aimed at stabilizing or improving clinical parameters in patients with progressive forms of multiple sclerosis.
- Other names
- hNSCshuman neural stem cellsallogeneic hNSCs
Beyond the preview
Go deeper on allogeneic human neural stem cells (Casa Sollievo della Sofferenza).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic human neural stem cells (Casa Sollievo della Sofferenza).